Pyruvate dehydrogenase complex (PDC) is an important enzyme complex in the body that plays a key role in energy metabolism and the production of ATP. It is a large, multi-subunit enzyme complex that is found in the mitochondria of all eukaryotic cells. PDC is responsible for the conversion of pyruvate, the end product of glycolysis, into acetyl-CoA, which is then used in the citric acid cycle for the production of ATP. In this article, we will discuss the structure, function, and importance of the pyruvate dehydrogenase complex.
The pyruvate dehydrogenase complex is composed of three different enzymes: pyruvate dehydrogenase (E1), dihydrolipoamide dehydrogenase (E2), and dihydrolipoamide transacetylase (E3). The E1 enzyme is a homodimer composed of two identical subunits, each containing a single active site. The E2 enzyme is a homotetramer composed of four identical subunits, each with a single active site. The E3 enzyme is a homodecamer composed of ten identical subunits, each with a single active site. The three enzymes are held together by non-covalent interactions.
The pyruvate dehydrogenase complex is responsible for the conversion of pyruvate to acetyl-CoA. This reaction involves the oxidation of pyruvate and the reduction of NAD+. The reaction is catalyzed by the E1 enzyme, which is a pyruvate dehydrogenase. The E1 enzyme converts pyruvate to a hydroxyethyl-TPP intermediate, which is then converted to acetyl-CoA by the E2 and E3 enzymes. The E2 enzyme is a dihydrolipoamide dehydrogenase, which catalyzes the oxidation of the hydroxyethyl-TPP intermediate and the reduction of NAD+. The E3 enzyme is a dihydrolipoamide transacetylase, which catalyzes the transfer of the acetyl group from the hydroxyethyl-TPP intermediate to coenzyme A.
The activity of the pyruvate dehydrogenase complex is regulated by several different mechanisms. The activity of the E1 enzyme is regulated by covalent modification, in which the enzyme can be phosphorylated or dephosphorylated. The activity of the E2 enzyme is regulated by allosteric inhibition, in which the enzyme is inhibited by the binding of NADH. The activity of the E3 enzyme is regulated by covalent modification, in which the enzyme can be phosphorylated or dephosphorylated.
The pyruvate dehydrogenase complex is an important enzyme complex that plays a key role in energy metabolism and the production of ATP. The PDC is responsible for the conversion of pyruvate, the end product of glycolysis, into acetyl-CoA, which is then used in the citric acid cycle for the production of ATP. In addition, the PDC is also involved in the regulation of fatty acid oxidation and gluconeogenesis.
The pyruvate dehydrogenase complex is a large, multi-subunit enzyme complex that is found in the mitochondria of all eukaryotic cells. It is responsible for the conversion of pyruvate to acetyl-CoA, which is then used in the citric acid cycle for the production of ATP. The activity of the PDC is regulated by several different mechanisms, including covalent modification and allosteric inhibition. The PDC is an important enzyme complex that plays a key role in energy metabolism and the production of ATP.
1.
Screening tests that are non-invasive show promise in detecting colorectal cancer.
2.
Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer
3.
The top three drugs for multiple myeloma treatment upfront are four.
4.
Taking vitamin D daily decreased cancer mortality, according to a study.
5.
New imaging technique identifies glioblastoma patients who would benefit from immunotherapy
1.
Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer
2.
The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective
3.
Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
The Pivotal Role of Telomerase in Breast Cancer Therapy Resistance and Treatment Strategies
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
3.
Navigating the Complexities of Ph Negative ALL - Part XII
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation